Passage Bio and Remix Therapeutics agree to all-stock merger deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026 4:05 PM EDTCombined company to operate as Remix Therapeutics and advance Remixs pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin
Remixs lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers
Concurrent oversubscribed $100 million private placement financing of Remix expected to fund combined company operations into 2028, supporting delivery of several clinical readouts for REM-422 in 2027
Companies to hold joint conference call on June 24, 2026 at 4:30 PM... More
